28.00 0.00 (0.00%)
After hours: 4:18PM EST
|Bid||27.00 x 1200|
|Ask||28.88 x 4000|
|Day's Range||27.70 - 30.48|
|52 Week Range||11.65 - 36.65|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||1.42|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.38|
Mallinckrodt continues to execute on its core business and could potentially move its Acthar franchise to stability or even growth, Steadman said in the Monday upgrade note. ◘ Challenges to Inomax — the company's treatment option for hypoxic respiratory failure in term and near-term infants — from a potential launch of competing products by Praxair or AIT Therapeutics Inc (OTC: AITB) do not pose a threat of erosion of the entire franchise, Steadman said.
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017, reflecting ~2% YoY growth. Xifaxan and Relistor primarily contributed to the revenue growth of Salix Pharmaceuticals in the third quarter. In the third quarter, Xifaxan and Relistor witnessed ~11% and 88% YoY organic revenue growth.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 15) Vapotherm, Inc. (NYSE: VAPO ) Down In The Dumps (Biotech ...
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 14) Vapotherm, Inc. (NYSE: VAPO )(listed following its IPO) ...
ST. LOUIS, Nov. 14, 2018 /PRNewswire/ -- SpecGx LLC (SpecGx), a subsidiary of Mallinckrodt plc (MNK) that operates its Specialty Generics business, today announced that, in a joint meeting, the U.S. Food and Drug Administration's (FDA's) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 10 to 7 to approve the SpecGx investigative abuse-deterrent formulation of immediate-release, single-entity oxycodone tablets for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 13) AstraZeneca plc (NYSE: AZN ) Down In The Dumps (Biotech ...
The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.
STAINES-UPON-THAMES, United Kingdom , Nov. 12, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, Dec. 12, 2018 ...
- In Post-Hoc Pooled Analysis of North American Studies, Investigational Agent Terlipressin Associated With Improvement in Survival in Patients with Hepatorenal Syndrome Type 1 with Low Baseline Mean Arterial ...
Mallinckrodt soared early Tuesday after the pharma stock outperformed quarterly views, though Eli Lilly was more muted on its mixed report.
-- Achievements Indicate Mallinckrodt Meets Standards and Regulations Among the Most Comprehensive for Medical Device Quality Management Systems -- STAINES-UPON-THAMES, United Kingdom , Nov. 8, 2018 /PRNewswire/ ...
NEW YORK, NY / ACCESSWIRE / November 7, 2018 / U.S. stocks closed in the green on Tuesday, with the Dow Jones rallying 173 points, as investors braced for the midterm election results. The Dow Jones Industrial ...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.67% and 0.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Check out the companies making headlines before the bell: Eli Lilly LLY – The drug giant reported adjusted quarterly profit of $1.39 per share, four cents above estimates, with revenue also beating Street forecasts.